BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, June 21, 2026
Home » Topics » Conferences, BioWorld Science

Conferences, BioWorld Science
Conferences, BioWorld Science RSS Feed RSS

Acute myeloid leukemia illustration
Cancer

BAL-0891 induces potent antileukemic effect in preclinical AML

June 19, 2025
No Comments

Sillajen Inc. has recently presented data regarding their threonine tyrosine kinase (TTK) and Polo-like kinase 1 (PLK1) dual inhibitor BAL-0891 as a therapeutic approach for acute myeloid leukemia (AML) treatment. The compound was tested both in vitro and in vivo in the preclinical setting.


Read More
Cancer

AZD-1390 + T-DXd shows synergy reducing tumor growth in TNBC

June 19, 2025
No Comments
About 30%-40% of triple-negative breast cancers (TNBC) show HER2-low status and may benefit from the HER2-directed antibody-drug conjugate trastuzumab deruxtecan (T-DXd). Ataxia-telangiectasia mutated (ATM) kinase plays a crucial role in double-strand break (DSB) repair response, thus inhibitors of ATM, such as AZD-1390, may enhance the effect of DSB inducers, resulting in DNA damage accumulation.
Read More
Microscopic image of acute myeloid leukemia (AML) cells.
Cancer

HPK1 inhibitor BGB-15025 exerts antileukemic activity in mice

June 18, 2025
No Comments
Despite an initial complete remission of 60%-80% in patients receiving anthracycline/cytarabine induction, acute myeloid leukemia (AML) shows a suboptimal long-term outcome rate. Serine/threonine kinase HPK1 has emerged as a promising therapeutic target, demonstrating pan-cancer prognostic significance.
Read More
Test tubes, dropper and capsules
Musculoskeletal

SAN-523 demonstrates anti-inflammatory efficacy in preclinical models of microcrystalline arthropathies

June 18, 2025
No Comments
University of Lausanne has reported promising preclinical data on SAN-523, a first-in-class positive allosteric modulator of cystathionine gamma-lyase (CSE), developed as a potential therapeutic for microcrystalline arthropathies, including gout and calcium pyrophosphate deposition (CPPD) disease.
Read More
Cancer tumor in breast illustration
Biomarkers

miR-7974 is a predictor of poor survival in ER+ breast cancer

June 18, 2025
No Comments
Estrogen receptor-positive (ER+) breast cancer remains a major challenge even with well-defined treatment options. The identification of reliable markers for early detection of the disease is crucial for improving patient outcomes.
Read More
3D representation of tumor microenvironment
Cancer

EACR 2025: Immune rewiring in cancer orchestrates tumor microenvironment

June 18, 2025
By Coia Dulsat
No Comments
Among the presentations included in the Top Abstracts category at the recently inaugurated Annual Congress of the European Association for Cancer Research (EACR) in Lisbon, it is worth highlighting two that respectively addressed the role of cytokines and lipid-sensing receptors as key modulators of the tumor microenvironment, a central theme in current cancer research.
Read More
Ernst Haeckel's 1874 drawings of embryonic development.
Cardiovascular

A human heart developed in a pig embryo over 21 days

June 17, 2025
By Mar de Miguel
No Comments
Chinese researchers are preparing the details for the publication of another scientific milestone, the creation of a chimera with a human heart and a kidney developed from human stem cells in pig embryos. These studies aim to address the shortage of immunocompatible organ donors while shedding light on some of the most fundamental questions in developmental biology.
Read More
Fibroblast illustration
Immune

AM-1476 inhibits 5-HT2B receptor with preclinical antifibrotic effects

June 17, 2025
No Comments
Systemic sclerosis (SSc) is a particularly severe form of fibrotic disease that affects multiple organs. SSc is the most deadly autoimmune rheumatic disease.
Read More
Musculoskeletal

New tracer has diagnostic utility for rheumatoid arthritis

June 17, 2025
No Comments
Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation and damage of the joints. PET/CT imaging is a useful tool for early disease assessment and monitoring treatment efficacy.
Read More
Amyloid beta peptides on neurons
Neurology/psychiatric

TMEM119 clears amyloid beta deposits in AD mice

June 17, 2025
No Comments
Alzheimer’s disease (AD) progression involves microglial activation, and restoring or maintaining microglia homeostasis is a therapeutic approach to fight against AD.
Read More
Previous 1 2 … 48 49 50 51 52 53 54 55 56 … 3091 3092 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 18, 2026.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 16, 2026
  • Wireframe of feet and scale

    GLP-1s need technologies for long-term use

    BioWorld
    For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
  • UTRN gene involved in arthrogryposis, study finds

    BioWorld Science
    Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
  • Blue-gray dollar sign

    HMNC raises $50M series B to prep depression drugs for phase III

    BioWorld
    HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing